Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.

17 Nov 2010

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Epigenomics AG , the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

Risk reduction of 20 ailments with regular exercise: Review

In a review article researchers have concluded that regular exercise cuts the risk of more than 20 illnesses. Some of these include colon cancer, heart disease, diabetes, osteoporosis and stroke said the study published in the International Journal of Clinical Practice.

16 Nov 2010

HUPTI's first group of patients complete prostate cancer treatment

The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

Protox decreases third quarter net and comprehensive loss to $1.6 million

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today released financial results for the third quarter, ended September 30, 2010.

15 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Regular exercise could reduce risk of developing physical, mental health conditions

People who take regular exercise could reduce their risk of developing around two dozen physical and mental health conditions including some cancers and dementia and slow down how quickly their body deteriorates as they age.

15 Nov 2010

Soligenix third quarter revenues increase to $861,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010.

12 Nov 2010

Hartford Hospital research team receives $238,000 grant from InHealth to study prostate cancer

The Institute for Health Technology Studies (InHealth) has awarded a grant totaling more than $238,000 to a research team at the Helen & Harry Gray Cancer Center at Hartford Hospital in Connecticut to study how various prostate cancer treatments affect a patient's "social capital" the ability to continue working productively in a paying job.

12 Nov 2010

$Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research$

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Research presented today at a national conference by a team of investigators at The Cancer Institute of New Jersey (CINJ), shows careful consideration should be given before initiating androgen deprivation therapy, a common treatment for older men with localized prostate cancer.

11 Nov 2010

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Risk reduction of 20 ailments with regular exercise: Review

HUPTI's first group of patients complete prostate cancer treatment

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Protox decreases third quarter net and comprehensive loss to $1.6 million

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

Regular exercise could reduce risk of developing physical, mental health conditions

Soligenix third quarter revenues increase to $861,000

Hartford Hospital research team receives $238,000 grant from InHealth to study prostate cancer

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in